002923.SZ
润都股份
SZSE · Healthcare · C 制造业 · CN
CNY 10.88
−3.55%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 1.3B | 1.2B | 1.2B | 1.3B | 1.4B |
| Cost of Revenue | 761.0M | 722.2M | 672.0M | 638.8M | 600.8M |
| Gross Profit | 509.3M | 454.2M | 510.4M | 653.1M | 771.4M |
| Operating Expenses | |||||
| R&D Expense | 82.8M | 94.1M | 131.3M | 129.4M | 95.6M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 86.9M | 86.0M | 67.2M | 79.1M | 72.6M |
| Selling & Marketing Expense | 308.9M | 260.4M | 245.8M | 314.6M | 389.6M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 511.1M | 470.4M | 472.7M | 551.9M | 577.9M |
| Cost and Expenses | 1.3B | 1.2B | 1.1B | 1.2B | 1.2B |
| Operating Income (EBIT) | (37.6M) | (51.7M) | 44.1M | 86.3M | 181.4M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | (45.5M) | (59.6M) | 42.6M | 86.0M | 180.9M |
| Income Tax Expense | 4.2M | 3.9M | 2.7M | 19.1M | 25.5M |
| Bottom Line | |||||
| Net Income | (49.7M) | (63.5M) | 39.9M | 66.9M | 155.5M |
| Earnings from Cont. Ops | (49.7M) | (63.5M) | 39.9M | 66.9M | 155.5M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (49.7M) | (63.5M) | 39.9M | 66.9M | 155.5M |
| Per Share | |||||
| Basic EPS | (CN¥0.15) | (CN¥0.19) | CN¥0.12 | CN¥0.20 | CN¥0.46 |
| Diluted EPS | (CN¥0.15) | (CN¥0.19) | CN¥0.12 | CN¥0.20 | CN¥0.46 |
| Revenue Per Share | CN¥4.07 | CN¥3.52 | CN¥3.56 | CN¥3.86 | CN¥4.06 |
| Shares | |||||
| Basic Shares Outstanding | 312.1M | 334.1M | 332.4M | 334.5M | 338.0M |
| Diluted Shares Outstanding | 312.1M | 334.1M | 332.4M | 334.5M | 338.0M |
| Profitability Metrics | |||||
| EBITDA | — | 96.1M | 184.0M | 201.8M | 256.6M |
| D&A | — | 147.8M | 139.9M | 115.5M | 75.3M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026